Skip to main content
. 2020 May 28;11:852. doi: 10.3389/fimmu.2020.00852

Figure 2.

Figure 2

Correlation of lnc-ITSN1-2 with IBD risk. (A) Comparison of intestinal mucosa lnc-ITSN1-2 among HC, A-CD, R-CD, A-UC, and R-UC; (B) ROC curve of intestinal mucosa lnc-ITSN1-2 (A-CD vs. HC); (C) ROC curve of intestinal mucosa lnc-ITSN1-2 (R-CD vs. HC); (D) ROC curve of intestinal mucosa lnc-ITSN1-2 (A-UC vs. HC); (E) ROC curve of intestinal mucosa lnc-ITSN1-2 (R-UC vs. HC); (F) ROC curve of intestinal mucosa lnc-ITSN1-2 (A-CD vs. R-CD); (G) ROC curve of intestinal mucosa lnc-ITSN1-2 (A-UC vs. R-UC); (H) Comparison of PBMC lnc-ITSN1-2 among HC, A-CD, R-CD, A-UC, and R-UC; (I) ROC curve of PBMC lnc-ITSN1-2 (A-CD vs. HC); (J) ROC curve of PBMC lnc-ITSN1-2 (R-CD vs. HC); (K) ROC curve of PBMC lnc-ITSN1-2 (A-UC vs. HC); (L) ROC curve of PBMC lnc-ITSN1-2 (R-UC vs. HC); (M) ROC curve of PBMC lnc-ITSN1-2 (A-CD vs. R-CD); (N) ROC curve of PBMC lnc-ITSN1-2 (A-UC vs. R-UC). IBD, inflammatory bowel disease; HC, health control; A-CD, active Crohn's disease; R-CD, Crohn's disease with remission; A-UC, active ulcerative colitis; R-UC, ulcerative colitis with remission; ROC, receiver operator characteristic; PBMC, peripheral blood mononuclear cells.